CN109715139A - 左旋多巴和卡比多巴肠凝胶以及使用方法 - Google Patents

左旋多巴和卡比多巴肠凝胶以及使用方法 Download PDF

Info

Publication number
CN109715139A
CN109715139A CN201780056836.5A CN201780056836A CN109715139A CN 109715139 A CN109715139 A CN 109715139A CN 201780056836 A CN201780056836 A CN 201780056836A CN 109715139 A CN109715139 A CN 109715139A
Authority
CN
China
Prior art keywords
pharmaceutical composition
levodopa
carbidopa
composition
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780056836.5A
Other languages
English (en)
Chinese (zh)
Inventor
A.迪奇
黄冶
J.M.利帕里
A.拉格尔斯
T.Y.段
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN109715139A publication Critical patent/CN109715139A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201780056836.5A 2016-07-20 2017-07-20 左旋多巴和卡比多巴肠凝胶以及使用方法 Pending CN109715139A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364770P 2016-07-20 2016-07-20
US62/364770 2016-07-20
PCT/US2017/043103 WO2018017850A1 (en) 2016-07-20 2017-07-20 Levodopa and carbidopa intestinal gel and methods of use

Publications (1)

Publication Number Publication Date
CN109715139A true CN109715139A (zh) 2019-05-03

Family

ID=59506369

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780056836.5A Pending CN109715139A (zh) 2016-07-20 2017-07-20 左旋多巴和卡比多巴肠凝胶以及使用方法

Country Status (9)

Country Link
US (4) US20180021280A1 (https=)
EP (1) EP3487479A1 (https=)
JP (3) JP2019523249A (https=)
CN (1) CN109715139A (https=)
AU (2) AU2017299710A1 (https=)
BR (1) BR112019001082A2 (https=)
CA (1) CA3031254A1 (https=)
MX (2) MX2019000849A (https=)
WO (1) WO2018017850A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
WO2021039084A1 (ja) * 2019-08-30 2021-03-04 テルモ株式会社 注射液製剤
EP4616878A1 (en) * 2024-03-15 2025-09-17 Cosmo Technologies Ltd. Cannula for rectal administration of an enema and compositions for use therewith

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2416736A1 (de) * 1973-04-09 1974-10-17 Takeda Chemical Industries Ltd Neue arzneimittelzubereitungen in form von waessrigen suspensionen
US5635213A (en) * 1992-11-30 1997-06-03 Neopharma Production Ab Pharmaceutical formulation
CN1901879A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 左旋多巴和卡比多巴的给药
CN101636145A (zh) * 2006-05-31 2010-01-27 索尔瓦药物有限公司 长期24小时经肠给予左旋多巴/卡比多巴
SE1451034A1 (sv) * 2014-09-04 2016-03-05 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, comt inhibitor and method of administration thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
DE102006034346B4 (de) * 2006-07-25 2008-11-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zum periodischen Messen der Fließgrenze von Dispersionen sowie deren Verwendung
US20150182688A1 (en) * 2013-12-31 2015-07-02 Abbvie Inc. Devices and methods for delivering a beneficial agent to a user
PT3782617T (pt) * 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2416736A1 (de) * 1973-04-09 1974-10-17 Takeda Chemical Industries Ltd Neue arzneimittelzubereitungen in form von waessrigen suspensionen
US5635213A (en) * 1992-11-30 1997-06-03 Neopharma Production Ab Pharmaceutical formulation
CN1901879A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 左旋多巴和卡比多巴的给药
CN101636145A (zh) * 2006-05-31 2010-01-27 索尔瓦药物有限公司 长期24小时经肠给予左旋多巴/卡比多巴
SE1451034A1 (sv) * 2014-09-04 2016-03-05 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, comt inhibitor and method of administration thereof

Also Published As

Publication number Publication date
WO2018017850A1 (en) 2018-01-25
EP3487479A1 (en) 2019-05-29
JP2019523249A (ja) 2019-08-22
JP2022166217A (ja) 2022-11-01
AU2017299710A1 (en) 2019-01-31
US20180021280A1 (en) 2018-01-25
JP2025000924A (ja) 2025-01-07
US20230129413A1 (en) 2023-04-27
BR112019001082A2 (pt) 2019-04-30
US20260014108A1 (en) 2026-01-15
CA3031254A1 (en) 2018-01-25
US20210059968A1 (en) 2021-03-04
MX2022014577A (es) 2023-01-11
MX2019000849A (es) 2019-09-13
AU2023203340A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP7232235B2 (ja) レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法
US20260014108A1 (en) Levodopa and Carbidopa Intestinal Gel and Methods of Use
WO2013144814A1 (en) Stable ready-to-use pharmaceutical composition of pemetrexed
KR20260003375A (ko) 주사용 제제
EP3281625B1 (en) Oral film preparation
WO2016008546A1 (en) Aqueous formulation comprising paracetamol and ibuprofen
MXPA04011530A (es) Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes.
JPWO2007055279A1 (ja) イオントフォレーシス用製剤
EP2656856A2 (en) Tablet formulation comprising levodopa, carbidopa, entacapone providing extended release
CN103417473B (zh) 一种阿达帕林凝胶剂及其制备方法
SE538425C2 (en) Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
JP2018065775A (ja) ナルフラフィン塩酸塩を含有するカプセル充填用組成物、軟カプセル剤及びその製造方法
TWI546087B (zh) Containing aqueous preparations of acetaminophen and ibuprofen
AU2006210560A1 (en) Method for reducing the level of peroxides in biocompatible polymer preparations
JPH04316515A (ja) 徐放性錠剤
WO2015183213A1 (en) Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination